Albumin injection: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
(New article generated using Special:MetadataForm)
 
imported>Howard C. Berkowitz
No edit summary
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Albumin injection''' is a protein extracted from human blood, which, when injected intravenously as a 5% solution, increases the volume and osmotic pressure of plasma. The primary indication is treatment of [[hypovolemia]], but it has some indications for severe edema secondary to [[renal]] and [[hepatic]] disease.
Since it is a natural blood product, it carries some risk of antigenicity and a low risk of infection; the supply also can be unpredictable.  The [[dextran]]s, one class of synthetic plasma expander, has no infection risk, but has its own problems of antigenicity. [[Hetastarch]] is considerably cheaper and has negligible risk of immune reaction. <ref>{{citation
| journal = Am J Hosp Pharm | date = January 1987 | volume = 44 | issue = 1 | pages =102-5.
| title = (Abstract) Changing use patterns of plasma volume expanders through educational intervention.
| author = Wong YY, Abramowitz PW, Mansur JM | url = http://www.ncbi.nlm.nih.gov/pubmed/2435148}}</ref>
==References==
{{reflist}}

Revision as of 22:44, 21 December 2010

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Albumin injection is a protein extracted from human blood, which, when injected intravenously as a 5% solution, increases the volume and osmotic pressure of plasma. The primary indication is treatment of hypovolemia, but it has some indications for severe edema secondary to renal and hepatic disease.

Since it is a natural blood product, it carries some risk of antigenicity and a low risk of infection; the supply also can be unpredictable. The dextrans, one class of synthetic plasma expander, has no infection risk, but has its own problems of antigenicity. Hetastarch is considerably cheaper and has negligible risk of immune reaction. [1]

References

  1. Wong YY, Abramowitz PW, Mansur JM (January 1987), "(Abstract) Changing use patterns of plasma volume expanders through educational intervention.", Am J Hosp Pharm 44 (1): 102-5.